190 Efficacy of azacitidine and predictive factors for response in MDS and AML patients in the Dutch compassionate patient named programme

MLA

van der Helm, L., et al. “190 Efficacy of Azacitidine and Predictive Factors for Response in MDS and AML Patients in the Dutch Compassionate Patient Named Programme.” Leukemia Research, vol. 35, Jan. 2011, p. S75. EBSCOhost, https://doi.org/10.1016/S0145-2126(11)70192-8.

APA

van der Helm, L., Alhan, C., Wijermans, P. W., van Marwijk Kooy, R., Schaafsma, R., Biemond, B. J., Beeker, A., Hoogendoorn, M., van Rees, B. P., de Weerdt, O., Wegman, J., Libourel, E. J., Luykx-de Bakker, S. A., Minnema, M. C., Brouwer, R. E., Croon-de Boer, F., Eefting, M., Jie, A., van de Loosdrecht, A. A., & Koedam, J. (2011). 190 Efficacy of azacitidine and predictive factors for response in MDS and AML patients in the Dutch compassionate patient named programme. Leukemia Research, 35, S75. https://doi.org/10.1016/S0145-2126(11)70192-8

Chicago

van der Helm, L., C. Alhan, P.W. Wijermans, R. van Marwijk Kooy, R. Schaafsma, B.J. Biemond, A. Beeker, et al. 2011. “190 Efficacy of Azacitidine and Predictive Factors for Response in MDS and AML Patients in the Dutch Compassionate Patient Named Programme.” Leukemia Research 35 (January): S75. doi:10.1016/S0145-2126(11)70192-8.